Denervation of the renal arteries in the treatment of resistant hypertension: Definition of the disease, patient selection and description of the procedure. Reference document 2012 of the Italian Society of Hypertension (SIIA);Denervazione delle arterie renali nel trattamento dell'ipertensione arteriosa resistente: Definizione della patologia, selezione dei pazienti e descrizione della procedura. Documento di indirizzo 2012 della Società Italiana dell'Ipertensione Arteriosa (SIIA)

Giornale Italiano di Cardiologia

Volumn 13, Issue 12, 2012, Pages 846-852

  Volpe, Massimo ^a   Agabiti Rosei, Enrico ^b   Ambrosioni, Ettore ^c   Cottone, Santina ^d   Cuspidi, Cesare ^e   Borghi, Claudio ^c   De Luca, Nicola ^f   Fallo, Francesco ^g   Ferri, Claudio ^h   Mancia, Giuseppe ^e   Morganti, Alberto ⁱ   Muiesan, Maria Lorenza ^b   Sarzani, Riccardo ^j   Sechi, Leonardo ^k   Tocci, Giuliano ^a   Virdis, Agostino ^l  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF L'AQUILA   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^k UNIVERSITY OF UDINE   (Italy)

^l UNIVERSITY OF PISA   (Italy)

more..

Author keywords

Antihypertensive therapy; Global cardiovascular risk; Refractory hypertension; Renal denervation; Resistant hypertension

Indexed keywords

ADRENERGIC ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CATHETER ABLATION; EFFERENT NERVE; JUXTAGLOMERULAR CELL; KIDNEY DENERVATION; MINIMALLY INVASIVE PROCEDURE; NON INSULIN DEPENDENT DIABETES MELLITUS; RENAL ARTERY; RESISTANT HYPERTENSION; REVIEW; SENSORY NERVE;

DENERVATION; HUMANS; HYPERTENSION; KIDNEY; PATIENT SELECTION;

EID: 84872078919     PISSN: 18276806     EISSN: 19726481     Source Type: Journal    
DOI: 10.1714/1188.13169     Document Type: Review

References (24)

1. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 2003;361:1629-41.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
3. Lewington S, Whitlock G, Clarke R, et al.; Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007;370:1829-39.
4. Turnbull F, Neal B, Algert C, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-9.
5. Turnbull F, Neal B, Ninomiya T, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3.
6. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
7. Zanchetti A, Mancia G, Black HR, et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009;27:673-9.
8. Bramlage P, Bohm M, Volpe M, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens 2010;12:666-77.
9. Dallongeville J, Banegas JR, Tubach F, et al.; EURIKA Investigators. Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol 2012;19:541-50.
10. Prugger C, Keil U, Wellmann J, et al.; EUROASPIRE III Study Group. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens 2011;29:1641-8.
11. Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N Engl J Med 2009;361:878-87.
12. Volpe M, Tocci G, Trimarco B, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007;25:1491-8.
13. Tocci G, Agabiti-Rosei E, Ambrosioni E, et al. Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens 2012;30:1065-74.
14. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-62.
15. Chapman N, Dobson J, Wilson S, et al.; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45.
16. Volpe M, Tocci G. Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. Expert Rev Cardiovasc Ther 2010;8:811-20.
17. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-57.
18. Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens 2012;30:837-41.
19. Schlaich MP, Krum H, Sobotka PA, Esler MD. Renal denervation and hypertension. Am J Hypertens 2011;24:635-42.
20. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009;54:1195-201.
21. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81.
22. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M; Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9.
23. Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012;23:1250-7.
24. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011;57:911-7.